{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T17:41:37Z","timestamp":1781026897674,"version":"3.54.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,22]],"date-time":"2013-07-22T00:00:00Z","timestamp":1374451200000},"content-version":"vor","delay-in-days":813,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Drug Policy"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1016\/j.drugpo.2011.02.004","type":"journal-article","created":{"date-parts":[[2011,3,16]],"date-time":"2011-03-16T19:39:26Z","timestamp":1300304366000},"page":"210-218","source":"Crossref","is-referenced-by-count":19,"title":["Harm reduction intensity\u2014Its role in HAART adherence amongst drug users in Amsterdam"],"prefix":"10.1016","volume":"22","author":[{"given":"Femke A.E.","family":"Lambers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ineke G.","family":"Stolte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte H.S.B.","family":"van den Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roel A.","family":"Coutinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Prins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.drugpo.2011.02.004_bib0005","doi-asserted-by":"crossref","first-page":"S376","DOI":"10.1086\/421400","article-title":"Developing a directly administered antiretroviral therapy intervention for HIV-infected drug users: Implications for program replication","volume":"38","author":"Altice","year":"2004","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.drugpo.2011.02.004_bib0010","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s11606-002-0044-3","article-title":"Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users","volume":"17","author":"Arnsten","year":"2002","journal-title":"Journal of General Internal Medicine"},{"issue":"2","key":"10.1016\/j.drugpo.2011.02.004_bib0015","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1097\/QAI.0b013e31815767d6","article-title":"Factors associated with antiretroviral therapy adherence and medication errors among HIV-infected injection drug users","volume":"46","author":"Arnsten","year":"2007","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.drugpo.2011.02.004_bib0020","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00228-007-0299-z","article-title":"Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily","volume":"63","author":"Arroyo","year":"2007","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1016\/j.drugpo.2011.02.004_bib0025","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1086\/507526","article-title":"Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression","volume":"43","author":"Bangsberg","year":"2006","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.drugpo.2011.02.004_bib0030","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/00126334-200004150-00006","article-title":"Impact of medical and nonmedical factors on physician decision making for HIV\/AIDS antiretroviral treatment","volume":"23","author":"Bogart","year":"2000","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.drugpo.2011.02.004_bib0035","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/01.qai.0000186364.27587.0e","article-title":"Factors associated with nonadherence to highly active antiretroviral therapy: A 5-year follow-up analysis with correction for the bias induced by missing data in the treatment maintenance phase","volume":"41","author":"Carrieri","year":"2006","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.drugpo.2011.02.004_bib0040","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1046\/j.1468-1293.2003.00130.x","article-title":"Assessing limiting factors to the acceptance of antiretroviral therapy in a large cohort of injecting drug users","volume":"4","author":"Clarke","year":"2003","journal-title":"HIV Medicine"},{"key":"10.1016\/j.drugpo.2011.02.004_bib0045","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1086\/322519","article-title":"Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users","volume":"33","author":"Clarke","year":"2001","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.drugpo.2011.02.004_bib0050","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1080\/09540120701351888","article-title":"The impact of illicit drug use and substance abuse treatment on adherence to HAART","volume":"19","author":"Hicks","year":"2007","journal-title":"AIDS Care"},{"key":"10.1016\/j.drugpo.2011.02.004_bib0055","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10461-006-9152-0","article-title":"Drug use and medication adherence among HIV-1 infected individuals","volume":"11","author":"Hinkin","year":"2007","journal-title":"AIDS and Behavior"},{"key":"10.1016\/j.drugpo.2011.02.004_bib0060","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/00952990701877052","article-title":"Impact of drug abuse treatment modalities on adherence to ART\/HAART among a cohort of HIV seropositive women","volume":"34","author":"Kapadia","year":"2008","journal-title":"American Journal of Drug and Alcohol Abuse"},{"key":"10.1016\/j.drugpo.2011.02.004_bib0065","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1080\/09540120412331319778","article-title":"Determinants of HAART discontinuation among injection drug users","volume":"17","author":"Kerr","year":"2005","journal-title":"AIDS Care"},{"key":"10.1016\/j.drugpo.2011.02.004_bib0070","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/01.qai.0000186392.26334.e3","article-title":"Individual, interpersonal, and structural correlates of effective HAART use among urban active injection drug users","volume":"41","author":"Knowlton","year":"2006","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"issue":"2","key":"10.1016\/j.drugpo.2011.02.004_bib0075","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1097\/QAI.0b013e31815767f8","article-title":"Microsocial environmental influences on highly active antiretroviral therapy outcomes among active injection drug users: The role of informal caregiving and household factors","volume":"46","author":"Knowlton","year":"2007","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.drugpo.2011.02.004_bib0080","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.drugpo.2009.08.003","article-title":"Social and structural determinants of HAART access and adherence among injection drug users","volume":"21","author":"Krusi","year":"2010","journal-title":"International Journal of Drug Policy"},{"key":"10.1016\/j.drugpo.2011.02.004_bib0085","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10461-007-9246-3","article-title":"The effects of housing status on health-related outcomes in people living with HIV: A systematic review of the literature","volume":"11","author":"Leaver","year":"2007","journal-title":"AIDS and Behavior"},{"key":"10.1016\/j.drugpo.2011.02.004_bib0090","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.drugpo.2007.05.002","article-title":"Antiretroviral HIV treatment and care for injecting drug users: An evidence-based overview","volume":"18","author":"Lert","year":"2007","journal-title":"International Journal of Drug Policy"},{"key":"10.1016\/j.drugpo.2011.02.004_bib0095","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00126334-200107010-00006","article-title":"Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection","volume":"27","author":"Lucas","year":"2001","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.drugpo.2011.02.004_bib0100","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/j.1360-0443.2008.02269.x","article-title":"Adherence to antiretroviral therapy for human immunodeficiency virus\/acquired immune deficiency syndrome among drug users: A systematic review","volume":"103","author":"Malta","year":"2008","journal-title":"Addiction"},{"key":"10.1016\/j.drugpo.2011.02.004_bib0105","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/00002030-200001280-00010","article-title":"Adherence to HAART in French HIV-infected injecting drug users: The contribution of buprenorphine drug maintenance treatment. The Manif 2000 study group","volume":"14","author":"Moatti","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.drugpo.2011.02.004_bib0110","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.drugalcdep.2006.02.003","article-title":"Antiretroviral adherence and HIV treatment outcomes among HIV\/HCV co-infected injection drug users: The role of methadone maintenance therapy","volume":"84","author":"Palepu","year":"2006","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.drugpo.2011.02.004_bib0115","doi-asserted-by":"crossref","first-page":"21","DOI":"10.7326\/0003-4819-133-1-200007040-00004","article-title":"Adherence to protease inhibitor therapy and outcomes in patients with HIV infection","volume":"133","author":"Paterson","year":"2000","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.drugpo.2011.02.004_bib0120","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1111\/j.1360-0443.2008.02323.x","article-title":"The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: Evidence from the MANIF2000 cohort study","volume":"103","author":"Roux","year":"2008","journal-title":"Addiction"},{"key":"10.1016\/j.drugpo.2011.02.004_bib0125","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/QAI.0b013e318050d8c2","article-title":"HIV-infected patients receiving lopinavir\/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%","volume":"45","author":"Shuter","year":"2007","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.drugpo.2011.02.004_bib0130","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/01.aids.0000216375.99560.a2","article-title":"Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion","volume":"20","author":"Smit","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.drugpo.2011.02.004_bib0135","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1360-0443.2006.01339.x","article-title":"Highly active antiretroviral therapy (HAART) among HIV-infected drug users: A prospective cohort study of sexual risk and injecting behaviour","volume":"101","author":"Smit","year":"2006","journal-title":"Addiction"},{"key":"10.1016\/j.drugpo.2011.02.004_bib0140","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.drugpo.2006.12.014","article-title":"Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST)","volume":"18","author":"Spire","year":"2007","journal-title":"International Journal of Drug Policy"},{"key":"10.1016\/j.drugpo.2011.02.004_bib0145","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/QAI.0b013e318061b5fd","article-title":"Methadone dosing strategies in HIV-infected injection drug users enrolled in a directly observed therapy program","volume":"45","author":"Tossonian","year":"2007","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.drugpo.2011.02.004_bib0150","series-title":"Report on the global AIDS epidemic 2006","author":"UNAIDS","year":"2007"},{"key":"10.1016\/j.drugpo.2011.02.004_bib0155","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1111\/j.1360-0443.2007.01912.x","article-title":"Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: Evidence from the Amsterdam Cohort Studies among drug users","volume":"102","author":"van den Berg","year":"2007","journal-title":"Addiction"},{"key":"10.1016\/j.drugpo.2011.02.004_bib0160","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00002030-198802000-00010","article-title":"Prevalence and risk factors of HIV infections among drug users and drug-using prostitutes in Amsterdam","volume":"2","author":"van den Hoek","year":"1988","journal-title":"AIDS"},{"key":"10.1016\/j.drugpo.2011.02.004_bib0165","series-title":"Adherence to long-term therapies: Evidence for action","author":"WHO","year":"2003"},{"key":"10.1016\/j.drugpo.2011.02.004_bib0170","series-title":"Towards universal access, scaling up priority HIV\/AIDS interventions in the health sector, progress report","author":"WHO","year":"2007"},{"key":"10.1016\/j.drugpo.2011.02.004_bib0175","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2307\/2531248","article-title":"Longitudinal data analysis for discrete and continuous outcomes","volume":"42","author":"Zeger","year":"1986","journal-title":"Biometrics"}],"container-title":["International Journal of Drug Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955395911000247?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955395911000247?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T11:34:35Z","timestamp":1637408075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955395911000247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["S0955395911000247"],"URL":"https:\/\/doi.org\/10.1016\/j.drugpo.2011.02.004","relation":{},"ISSN":["0955-3959"],"issn-type":[{"value":"0955-3959","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]}}}